Emerging studies suggest Retatrutide , a dual stimulator targeting both incretin and glucose-dependent insulinotropic polypeptide , may provide a promising development for obesity treatment. Early human investigations have shown impressive reductions in visceral mass , possibly outperforming current weight-loss treatments. Despite this, additional